Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement [Yahoo! Finance]
Kintara Therapeutics, Inc. (KTRA)
Company Research
Source: Yahoo! Finance
therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway $31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025 TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunities Companies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ET SAN DIEGO, CA AND TAMPA, FL / ACCESSWIRE / April 3, 2024 / Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that they have entered into a definitive agreement for an all-stock transaction forming a company with exper
Show less
Read more
Impact Snapshot
Event Time:
KTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KTRA alerts
High impacting Kintara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KTRA
News
- TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRAPR Newswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRAPR Newswire
- Lifshitz Law PLLC Announces Investigations of KTRA, CHX, PIK, and LABPAccesswire
- KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRABusiness Wire
KTRA
Sec Filings
- 4/25/24 - Form 425
- 4/25/24 - Form 8-K
- 4/3/24 - Form 425
- KTRA's page on the SEC website